about
Requirements for receptor engagement during infection by adenovirus complexed with blood coagulation factor XAngiotensin-(1-9) attenuates cardiac fibrosis in the stroke-prone spontaneously hypertensive rat via the angiotensin type 2 receptorAngiotensin1-9 antagonises pro-hypertrophic signalling in cardiomyocytes via the angiotensin type 2 receptorCardiac Hypertrophy Is Inhibited by a Local Pool of cAMP Regulated by Phosphodiesterase 2Novelty and SignificanceGenome-wide association study of blood pressure extremes identifies variant near UMOD associated with hypertension.Targeted gene delivery to vascular tissue in vivo by tropism-modified adeno-associated virus vectors.Development of efficient viral vectors selective for vascular smooth muscle cells.Vascular bed-targeted in vivo gene delivery using tropism-modified adeno-associated viruses.Development of renal-targeted vectors through combined in vivo phage display and capsid engineering of adenoviral fibers from serotype 19p.Defining a Novel Role for the Coxsackievirus and Adenovirus Receptor in Human Adenovirus Serotype 5 Transduction In Vitro in the Presence of Mouse Serum.Use of in vivo phage display to engineer novel adenoviruses for targeted delivery to the cardiac vasculature.Third-generation lentivirus vectors efficiently transduce and phenotypically modify vascular cells: implications for gene therapy.Biodistribution and retargeting of FX-binding ablated adenovirus serotype 5 vectorsAdenoviral delivery of angiotensin-(1-7) or angiotensin-(1-9) inhibits cardiomyocyte hypertrophy via the mas or angiotensin type 2 receptorTropism-modified adenoviral and adeno-associated viral vectors for gene therapy.Targeting gene therapy vectors to the vascular endothelium.Manipulating adenovirus hexon hypervariable loops dictates immune neutralisation and coagulation factor X-dependent cell interaction in vitro and in vivoPromoters and control elements: designing expression cassettes for gene therapy.Cell-selective viral gene delivery vectors for the vasculature.The influence of adenovirus fiber structure and function on vector development for gene therapy.Ad5:Ad48 hexon hypervariable region substitutions lead to toxicity and increased inflammatory responses following intravenous deliveryNovel vectors for in vivo gene delivery to vascular tissue.The relevance of coagulation factor X protection of adenoviruses in human sera.G-Protein-Coupled Receptor 35 Mediates Human Saphenous Vein Vascular Smooth Muscle Cell Migration and Endothelial Cell Proliferation.Interactions of adenovirus vectors with blood: implications for intravascular gene therapy applications.Identification of coagulation factor (F)X binding sites on the adenovirus serotype 5 hexon: effect of mutagenesis on FX interactions and gene transfer.The antiallergic mast cell stabilizers lodoxamide and bufrolin as the first high and equipotent agonists of human and rat GPR35Prevention of coronary in-stent restenosis and vein graft failure: does vascular gene therapy have a role?Regulation of cardiovascular remodeling by the counter-regulatory axis of the renin-angiotensin system.Angiotensin-(1-7) and angiotensin-(1-9): function in cardiac and vascular remodelling.The importance of coagulation factors binding to adenovirus: historical perspectives and implications for gene delivery.Adenovirus 5 fibers mutated at the putative HSPG-binding site show restricted retargeting with targeting peptides in the HI loop.In vitro and in vivo characterisation of endothelial cell selective adenoviral vectors.G protein-coupled receptor 35: an emerging target in inflammatory and cardiovascular disease.Electrical consequences of cardiac myocyte: fibroblast coupling.Tropism-modification strategies for targeted gene delivery using adenoviral vectors.Retargeting FX-binding-ablated HAdV-5 to vascular cells by inclusion of the RGD-4C peptide in hexon hypervariable region 7 and the HI loop.Efficient transduction of primary vascular cells by the rare adenovirus serotype 49 vector.Combined therapeutic benefit of mitochondria-targeted antioxidant, MitoQ10, and angiotensin receptor blocker, losartan, on cardiovascular function.Gene Therapy With Angiotensin-(1-9) Preserves Left Ventricular Systolic Function After Myocardial Infarction
P50
Q28475714-B52D81D0-ECB7-4730-9669-A59D35435BB4Q28565979-399740C4-F8A9-4DF6-A033-262F148E70B4Q28566391-763BABF1-4447-4CC9-8807-F5049B093A63Q29397067-B7E8665B-AC8B-4C0F-BBB3-FD91B41C6EBAQ29417122-28272351-8439-40E6-AB55-A6FEE34F568DQ31036743-0BD6CF58-6D5F-4129-A895-F3EFCEBBB3E2Q33197377-2B024A28-ED12-46B6-8A1D-3423BEFC65A7Q33230629-3EEFB596-4F36-431F-91CD-4B17B87D083AQ33286806-A6BCF4F6-F59A-4E86-92FD-E11D06B53EF2Q33440718-AD8A839A-CCDC-4163-ACA3-C8B6361EBE7CQ33456433-2B4C93B3-37FC-4623-94DD-4899731AF00EQ34207550-F70C762D-DAD8-4E17-B6FB-A34FDD77B62DQ34282191-EFD7AE42-6538-4539-99F7-DF5F9F33147EQ34429431-570BC6FF-3305-48B6-ACA4-01C6C0EEFF6DQ34791438-26F23133-3346-49FD-85B7-0F8A356BF2F0Q35095393-45E8BCAD-8B7C-4494-9EB6-1C7DBA60C956Q35557004-1F623D67-1249-42FF-93D9-B22F9592CCA2Q35698680-C300F95F-F3D0-4067-B762-FD2398C4430BQ35948498-9C4FA0FB-E61A-4649-814B-4BB00E4F93A5Q36182171-363790A6-82CD-4BB3-A8FF-E789028C4F01Q36445557-31FF4905-DEE8-45FC-8D0E-0CADAB5F28FEQ36842711-DD002EBB-99EA-4435-B1BE-8169DDFA614FQ37085147-6F6D11A1-6E40-4F4C-AB56-1AAF928E68B2Q37122933-CA0D1B72-4CB1-4617-B3BC-71B8EA9B1B09Q37284881-D0A944BB-232B-4DE9-AD68-F39FCFD8492AQ37291653-62202AD5-87C2-43B1-A251-DB60D272CAACQ37405405-D14BCF4E-398A-4A83-9A6B-7BF2125760BBQ38026374-7317B185-02AA-4188-8BC7-291A55A4273CQ38069197-DF9229F0-69EE-452B-8188-0A684DE2307BQ38193206-1966C0B3-BD2D-4AA2-B449-74BA262580ACQ38230901-D7F38D7F-CA26-40BF-BED6-BDC08234A600Q38305480-C0459DEF-BC62-47CE-BF9F-3242BD0171E0Q38343485-26C7D2AD-6816-4D7D-9572-73B21B635AAAQ38389922-E4D4F8D1-921E-4CF4-A1F2-6912F6A44AABQ38502124-91CF8997-9E00-4960-BABA-3CA6A63A11D3Q38614156-63E524E1-AEEF-41B3-98A8-146A03B23079Q38866016-2E804179-BD60-4582-A6FF-9DB8A80DB581Q38901143-1CAEA467-E70A-4A9E-8F34-C1A65A041CCFQ39048039-EC2F9132-A791-4F5D-87F9-393E9092ED56Q39097850-78DA60EF-7BC8-45B7-9955-5BC983302756
P50
description
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Stuart A Nicklin
@ast
Stuart A Nicklin
@en
Stuart A Nicklin
@es
Stuart A Nicklin
@nl
Stuart A Nicklin
@sl
type
label
Stuart A Nicklin
@ast
Stuart A Nicklin
@en
Stuart A Nicklin
@es
Stuart A Nicklin
@nl
Stuart A Nicklin
@sl
altLabel
Stuart Nicklin
@en
prefLabel
Stuart A Nicklin
@ast
Stuart A Nicklin
@en
Stuart A Nicklin
@es
Stuart A Nicklin
@nl
Stuart A Nicklin
@sl
P106
P21
P31
P496
0000-0002-9691-6210